Genentech announced results from coBRIM, a Phase 3 trial evaluating cobimetinib in combination with Zelboraf (vemurafenib) in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAFV600 mutation. Cobimetinib is a selective inhibitor that blocks the activity of MEK, a protein kinase that is part of the RAS-RAF-MEK-ERK pathway that promotes cell division and survival.

coBRIM is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of cobimetinib in combination with vemurafenib, compared to vemurafenib alone, in 495 patients. The primary endpoint for coBRIM is progression-free survival.

RELATED: Superior Overall Survival with Nivolumab in Skin Cancer Trial

The primary endpoint in the study was met with a statistically significant increase in progression-free survival (PFS) for the combination of cobimetinib plus vemurafenib as compared to vemurafenib alone.

For more information call (800) 821-8590 or visit